Vitamin Supplement
Vitamin D for Sickle Cell Anemia
Recruiting0 awardsPhase 2
New York, New York
This trial tests if vitamin D3 can lower lung issues in kids with sickle cell disease. It compares different dosing schedules to see which works better. The goal is to find a simple, low-cost way to help these children stay healthier. Vitamin D has been studied for its potential to reduce respiratory complications in children with sickle cell disease due to its ability to fight infections and support the immune system.
Dual PI3K/mTOR Inhibitor
BEZ235 +1 More for Upper Respiratory Tract Infection
Recruiting1 awardPhase 2
Wichita, Kansas
The purpose of this study is to evaluate the efficacy, tolerability, and safety of BEZ235 alone and in combination with RAD001 to support further development to reduce the incidence of respiratory tract infections (RTIs) in elderly subjects.
CAR T-cell Therapy
VST Therapy for Post-Transplant Viral Infections
Recruiting1 awardPhase 1
Washington, District of Columbia
This trial is designed to evaluate the safety of rapidly generated multivirus-specific T-cell products with antiviral activity against CMV, EBV, adenovirus, HHV6, BK virus, JC virus, and human parainfluenza-3 (HPIV3), derived from eligible HSCT donors.
Popular Filters
Trials for Respiratory Syncytial Virus Patients
Monoclonal Antibodies
Clesrovimab for Respiratory Syncytial Virus
Recruiting1 awardPhase 3
Greenville, South Carolina
This trial is testing two medications, clesrovimab and palivizumab, to see if they are safe and well-tolerated by people who might need them. The study will look at any side effects experienced by participants. Palivizumab is a treatment approved in 1998 for high-risk children against respiratory infections and is now approved in over 45 countries.
Virus Therapy
RSV Vaccine for Respiratory Syncytial Virus
Recruiting0 awardsPhase 1
Baltimore, Maryland
This trial tests a new RSV vaccine given as nose drops to help protect against lung infections caused by the RSV virus. It involves healthy children and infants, including those who have and have not had an RSV infection before. The vaccine works by teaching the body to recognize and fight the virus.
Placebo +2 More for Respiratory Syncytial Virus
Recruiting0 awardsPhase 1
Baltimore, Maryland
The purpose of this study is to evaluate the infectivity, safety, and immunogenicity of the recombinant live-attenuated respiratory syncytial virus (RSV) vaccines RSV ΔNS2/Δ1313/I1314L or RSV 276 or placebo when delivered as nose drops to RSV-seronegative infants and children 6 to 24 months of age. This study is a companion study to IMPAACT 2018.
Virus Therapy
RSV Vaccine for Older Adults
Recruiting2 awardsPhase 3
Mobile, Alabama
This trial is testing a new RSV vaccine by GSK in adults aged 60 and above. The vaccine aims to boost the immune system's ability to fight RSV. The study will also look at how safe the vaccine is and how long its effects last.
Virus Therapy
mRNA-1345 Vaccine for Respiratory Syncytial Virus
Recruiting0 awardsPhase 2 & 3
La Mesa, California
This trial is testing a new vaccine called mRNA-1345 to see if it can prevent lung infections caused by the RSV virus. The vaccine works by teaching the body to recognize and fight the virus. The study will include people who are at risk of these infections and will compare the effects of the vaccine to a non-treatment group.
Trials for Respiratory Syncytial Virus Infection Patients
Virus Therapy
RSV Vaccine for Respiratory Syncytial Virus
Recruiting0 awardsPhase 1
Baltimore, Maryland
This trial tests a new RSV vaccine given as nose drops to help protect against lung infections caused by the RSV virus. It involves healthy children and infants, including those who have and have not had an RSV infection before. The vaccine works by teaching the body to recognize and fight the virus.
Virus Therapy
RSV Vaccine for Older Adults
Recruiting2 awardsPhase 3
Mobile, Alabama
This trial is testing a new RSV vaccine by GSK in adults aged 60 and above. The vaccine aims to boost the immune system's ability to fight RSV. The study will also look at how safe the vaccine is and how long its effects last.
Phase 3 Trials
Monoclonal Antibodies
Clesrovimab for Respiratory Syncytial Virus
Recruiting1 awardPhase 3
Greenville, South Carolina
This trial is testing two medications, clesrovimab and palivizumab, to see if they are safe and well-tolerated by people who might need them. The study will look at any side effects experienced by participants. Palivizumab is a treatment approved in 1998 for high-risk children against respiratory infections and is now approved in over 45 countries.
Virus Therapy
Lenacapavir for HIV Prevention
Recruiting1 awardPhase 3
Los Angeles, California
This trial is testing lenacapavir, a drug that may help prevent HIV. It targets people who are at risk of getting HIV. The drug works by stopping the virus from making more copies of itself. Lenacapavir was developed by Gilead Sciences Inc. and has been approved for use in combination with other treatments.
Virus Therapy
DAS181 for Respiratory Infections
Recruiting1 awardPhase 3
Duarte, California
This trial will enroll immunocompromised patients with Lower Tract parainfluenza infection to study the safety and efficacy of an investigational vaccine. A sub-study will also enroll patients with severe COVID-19.
Virus Therapy
Pritelivir vs Foscarnet for Resistant Herpes
Recruiting2 awardsPhase 3
New Haven, Connecticut
This trial compares two treatments for herpes infections in patients with weakened immune systems who do not respond to standard treatment. One treatment is a pill called pritelivir, and the other is a drug called foscarnet. Both aim to stop the virus from replicating and help heal sores. Foscarnet has been used to treat herpes viruses, including drug-resistant cytomegalovirus (CMV) and herpes simplex viruses types 1 and 2 (HSV-1 and HSV-2).
Pathogen Reduction System
INTERCEPT Blood System for Blood Transfusion Safety
Recruiting2 awardsPhase 3
New Haven, Connecticut
This trial is designed to study the safety and efficacy of the INTERCEPT Blood System for pathogen reduction of red blood cells in comparison to conventional methods. If successful, the system may be made available in areas where transfusion-transmissible infections are common.
Trials With No Placebo
Monoclonal Antibodies
Lenvatinib + Pembrolizumab for Respiratory Papillomatosis
Recruiting1 awardPhase 2
Boston, Massachusetts
This trial is studying how well Lenvatinib in combination with Pembrolizumab works in treating patients with human papillomavirus (HPV)-associated recurrent respiratory papillomatosis (RRP).
Trials Offering Remuneration
Virus Therapy
RSV Vaccine for Respiratory Syncytial Virus
Recruiting0 awardsPhase 1
Baltimore, Maryland
This trial tests a new RSV vaccine given as nose drops to help protect against lung infections caused by the RSV virus. It involves healthy children and infants, including those who have and have not had an RSV infection before. The vaccine works by teaching the body to recognize and fight the virus.
Placebo +2 More for Respiratory Syncytial Virus
Recruiting0 awardsPhase 1
Baltimore, Maryland
The purpose of this study is to evaluate the infectivity, safety, and immunogenicity of the recombinant live-attenuated respiratory syncytial virus (RSV) vaccines RSV ΔNS2/Δ1313/I1314L or RSV 276 or placebo when delivered as nose drops to RSV-seronegative infants and children 6 to 24 months of age. This study is a companion study to IMPAACT 2018.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.